Highlights:
• Last patient enrolled and safely dosed, completing patient recruitment for EOC Pharma’s phase I studyin metastatic breast cancer (MBC)
• Data expected throughout 2020, with study completion in Q4 CY2020• Registration trial in MBC in China is planned
For more information, please download the attached PDF
Download this document